XTLB — XTL BIOPHARMACEUTICALS LTD

Nasdaq · Health Care · Pharmaceuticals · CIK 1023549 ·
Last close
$2.91
Market Cap
$7.15M
52W High
$4.87
52W Low
$2.01
ADV30
140,004
Next earnings
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 166,000 76,000 420,000
Jun 2025 714,000 150,000 761,000
Dec 2024 289,000 -43,000 -812,000 -255,000 8,550,000 371,000 3,115,000
Sep 2024 162,000 -764,000 -553,000 9,280,000 820,000 3,563,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-159,009,000
Inventory
Receivables
$150,000
ST Investments
$772,000
EBIT TTM
$-939,000
Pretax Income TTM
$-938,000
Interest Exp TTM
$-1,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$968,000
EBITDA
$-1,266,000
Free Cash Flow
$-2,116,000
Enterprise Value
$7,026,069
Total Cash
$76,000
Total Debt
$0
Shares Out
2,457,463
Trailing EPS
$-0.36
Book Value
$0.00
ROE
-29.3%
ROA
-21.0%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -1,380,000 -6,969,000 166,000 420,000 -1,025,000
Dec 2024 451,000 -2,172,000 -1,027,000 8,550,000 3,115,000 -1,618,000
Dec 2023 0 -765,000 -1,782,000 2,426,000 206,000 -707,000
Dec 2022 0 -880,000 -1,348,000 4,186,000 187,000 -901,000
Dec 2021

Peers — same industry

TickerNameMarket CapLastDaily %
NXTC NextCure, Inc. $7.12M $1.97
AVCRF Avricore Health Inc. $7.08M $0.06
ERNA Ernexa Therapeutics Inc. $7.07M $6.06
BOLT Bolt Biotherapeutics, Inc. $7.26M $3.78
HCWB HCW Biologics Inc. $7.27M $4.55

News headlines (Yahoo Finance, 1h cache)

XTL Completed the Acquisition of Psyga Bio Ltd.
2026-06-30 21:15 · Yahoo
XTL Announces Receipt of Staff Delist Determination from Nasdaq
2026-05-22 20:10 · Yahoo
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologi
2026-04-29 12:58 · Yahoo
XTL Biopharmaceuticals Announces ADS Ratio Change
2026-03-20 20:10 · Yahoo
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
2026-02-27 21:30 · Yahoo
XTL Update on Recent Developments
2026-01-29 21:05 · Yahoo
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
2026-01-23 21:10 · Yahoo
Top Midday Gainers
2026-01-13 18:54 · Yahoo
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
2026-01-13 14:28 · Yahoo
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
2026-01-13 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.